Log in

APMD Apnimed, Inc. NASDAQ · United States

Apnimed (APMD) news APMD going concern and IPO news

Financings ·

Apnimed prices IPO of 12,000,000 shares at $16.00

Apnimed priced 12,000,000 shares at $16.00 for $192,000,000 before fees. The company has no approved drug, a secured term loan, and a going-concern warning in its prospectus.

Latest Apnimed news

  1. Financings

    Apnimed files for IPO, plans Nasdaq Global Market listing as APMD

    Apnimed, Inc. filed a Form S-1 with a preliminary prospectus dated July 10, 2026. The cover leaves the share count and price range blank, and the company has no approved drug yet.

Questions about Apnimed

Has Apnimed issued a going-concern warning?

Our latest story on this, dated Jul 31, 2026: "Apnimed prices IPO of 12,000,000 shares at $16.00". The story links the filing or release it is based on. Read the story.

When did Apnimed go public?

Our latest story on this, dated Jul 31, 2026: "Apnimed prices IPO of 12,000,000 shares at $16.00". The story links the filing or release it is based on. Read the story.

What is the ticker symbol of Apnimed?

Apnimed, Inc. trades under the ticker APMD on NASDAQ.

Where is Apnimed listed?

Apnimed, Inc. is listed on NASDAQ.

What is the SEC CIK of Apnimed?

The SEC Central Index Key (CIK) for Apnimed, Inc. is 1745648. Its filings are on SEC EDGAR.

How many shares does Apnimed have outstanding?

41,630,779 shares as of 2026-09-04, per the cover page of its 10-Q filed 2026-09-08.

Which country or territory is Apnimed listed under?

Our directory records Apnimed, Inc. under United States.

What does Apnimed do?

Our directory classifies Apnimed, Inc. as: Biotechnology. This is a directory classification, not a description of the pipeline.

What is the ISIN of Apnimed?

The ISIN recorded for Apnimed, Inc. is US03770Y1073.

Does aibio.space cover Apnimed?

aibio.space lists Apnimed, Inc. among 2,820 public biotech companies and publishes its news here as stories appear.

Where is Apnimed incorporated?

SEC records list its state or country of incorporation as DE.

What is the latest Apnimed (APMD) stock news?

Our latest story on Apnimed, dated Jul 31, 2026: "Apnimed prices IPO of 12,000,000 shares at $16.00". Apnimed priced 12,000,000 shares at $16.00 for $192,000,000 before fees. The company has no approved drug, a secured term loan, and a going-concern warning in its prospectus. Source.

What is Apnimed's latest stock offering or financing news?

Our latest financing story, dated Jul 31, 2026: "Apnimed prices IPO of 12,000,000 shares at $16.00". Apnimed priced 12,000,000 shares at $16.00 for $192,000,000 before fees. The company has no approved drug, a secured term loan, and a going-concern warning in its prospectus. Source.

Who were the underwriters or placement agents on Apnimed's offering?

From our story: In April 2026 Apnimed signed a credit agreement for up to $150.0 million of term loans, with HCR OSA SPV, LLC as administrative and collateral agent. Source.

How long will Apnimed's cash last?

From our story of Jul 31, 2026: The company has no approved drug, a secured term loan, and a going-concern warning in its prospectus. Source.

Investor discussion: Apnimed

Members talk about Apnimed (APMD). Reader posts, not aibio.space reporting, and not investment advice.

Rules
  1. Securities violations are strictly forbidden. No market manipulation, no pump-and-dump, no false or misleading statements, and no inside information.
  2. Say whether you hold the stock. Every post states long, short or no position.
  3. No paid or sponsored posts. Do not post for anyone who pays or rewards you.
  4. No buy or sell calls and no price targets.
  5. No accusations of crime or fraud against named people unless you link a court filing or a regulator's release that makes them.
  6. No personal details and no spam. No links at all for your first 7 days as a member.

Posts that break the rules may be deleted without notice, and the account restricted or closed. See the terms and the privacy policy.

Capital-markets timeline

Financings, listing notices, splits, legal actions and other investor events at Apnimed, newest first. Each line links the filing it comes from.

  1. Distress

    Reported substantial doubt about its ability to continue as a going concern. SEC Form 10-Q. Source

  2. Financings

    Filed a final prospectus for a securities offering. SEC Form 424B4. Source

  3. Financings

    Filed a registration statement for a share offering. SEC Form S-1. Source

Stock chart

Price chart and quote supplied by TradingView, delayed as the exchange requires. It loads only if you choose to show it. Information only, not investment advice. Open NASDAQ:APMD on TradingView.

SEC filings and registration

SEC name
Apnimed, Inc.
CIK
1745648
Industry (SIC)
Pharmaceutical Preparations (2834)
US tickers
APMD (Nasdaq)
State or country of incorporation
DE
Fiscal year ends
December 31
Filer category
Non-accelerated filer<br>Smaller reporting company<br>Emerging growth company
Business address
39 JOHN F. KENNEDY STREET, 4TH FLR., CAMBRIDGE, MA, 02138
Phone
617-500-8880
Shares outstanding
41,630,779 as of 2026-09-04 (10-Q filed 2026-09-08)

Recent filings (8-K and 6-K are the company's own announcements)

  • 10-Q filed 2026-09-08
  • 8-K filed 2026-09-08
  • 8-K filed 2026-08-03
  • S-1 filed 2026-07-10

Source: SEC EDGAR, retrieved October 23, 2026. Shares outstanding is the cover-page figure from the latest periodic report. The SEC does not publish share prices.

Listing details

Apnimed, Inc. is a public biotech or pharmaceutical company listed on NASDAQ under the ticker APMD, recorded under United States. The directory classifies it as Biotechnology. aibio.space tracks 2,820 public biotech companies worldwide and publishes investor news on them.

Company
Apnimed, Inc.
Ticker
APMD
Listing
NASDAQ
Country or territory
United States
Business scope
Biotechnology
ISIN
US03770Y1073
Last quote in directory
2026-10-21
Directory source
Listing page

Listing facts come from our company directory, researched on October 22, 2026. A listing record does not certify that a security currently trades. Tell us about a change. Work at this company? Claim this page.

Published and maintained by aibio.space. Not investment advice. How we work.

Who manages this page This page is managed by aibio.space. The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. How we work · Terms · Request a correction

aibio.space

Full desks

Every other company has a starter desk. Search above to open one.

Settings

Appearance
Text size
Motion

Stops the news strip and the share rollers.

Your choices are saved in this browser only.

Free membership

Read aibio.space in full, free

Subscribe with your email address to read every story, company desk and profile in full. It costs nothing. In return, you agree that we may email you, including offers. One click to unsubscribe.

No card, no password. With email, we send one message to confirm your address first. With Google or Facebook we receive only your email address. Not investment advice.